Plain-English translation of NCT05706896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This pilot study is testing whether injections of umbilical cord blood platelet-rich plasma (CB-PRP) — a treatment derived from donated umbilical cord blood — can help slow or stop vision loss in people with dry age-related macular degeneration (AMD), a common eye condition affecting older adults. Researchers will inject the medication into one eye while giving a placebo (sham) injection into the other eye to see if the treatment works. The study will test three different injection schedules to find the best approach.
Dry AMD causes progressive vision loss and currently has very limited treatment options. This study is exploring whether this medication, which is rich in healing compounds, might help protect the eye and slow the damage caused by this condition.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive a series of injections into one eye, while your other eye receives a placebo injection for comparison. Depending on which group you're assigned to, you'll receive injections either monthly (12 times), every two months (6 times), or every three months (4 times) over the course of the study. Your vision and eye health will be monitored carefully throughout the trial to track whether the treatment helps slow your vision loss.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy